Brind.

Jefferies backs AstraZeneca's sales ambition, noting Baxfendy for hypertension and tozorakimab as a potential COPD treatment.

1 report, 1 independent Updated Wed 16:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jefferies backs AstraZeneca's sales ambition, noting Baxfendy for hypertension and tozorakimab as a potential COPD treatment.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped